1. Home
  2. All press releases

Innate Pharma moves forward anti-KIR monoclonal antibody IPH 2101 development with study extension in acute myeloid leukemia

  • Other Phase I/II or IIa trials are planned with this drug candidate
  • In the context of the French new "anti-cancer plan" announcement, IPH 2101 was presented to government officials
PR in english 57.8 KB
CP en français 52.44 KB